Taru S. Dutt1†
Robert Krause2†
David Hertz3†
Marcela Henao-Tamayo4*‡
Alasdair Leslie2,5*‡
Bianca Schneider3*‡- 1Division of Laboratory Medicine, Department of Pathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States
- 2Africa Health Research Institute, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa
- 3Host Determinants in Lung Infections, Priority Research Area Infections, Research Center Borstel, Leibniz Lung Center, Borstel, Germany
- 4Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United States
- 5Department of Infection and Immunity, University College London, London, United Kingdom
B cells play a crucial role in immunity against various infectious diseases. However, their role in tuberculosis (TB) has been largely understudied. Emerging evidence suggests that B cells actively shape immune responses in TB. Beyond their classical functions, B cells contribute to the formation of inducible bronchus-associated lymphoid tissue (iBALT), a tertiary lymphoid structure (TLS) that enhances localized immune responses in the lungs. As iBALT is a site for B-T cell interactions and the generation of high-affinity antibodies, recent studies suggest that sex differences in iBALT formation influence TB immunity. This review synthesizes evidence from both TB and non-TB models to highlight the expanding role of B cells and iBALT, underscoring their potential implications for vaccine development and immunotherapy.
1 Introduction
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a leading cause of infectious disease-related mortality worldwide (1). Despite extensive research efforts, developing an effective vaccine beyond Bacille Calmette-Guérin (BCG) continues to face substantial hurdles (2, 3). This challenge is partly due to the limited understanding of the mechanisms underlying protective immunity and the distinction between beneficial and pathogenic immune responses (4, 5). Given the intracellular nature of Mtb, TB research has traditionally centered on T cell-mediated immune responses (6–10). While T cells are undoubtedly essential, emerging evidence highlights the previously underappreciated role of B cells in TB immunity (11–16). Beyond their classical function of antibody production, B cells contribute significantly to antigen presentation (17), cytokine secretion (18, 19), and the formation of tertiary lymphoid structures (TLS), such as inducible bronchus-associated lymphoid tissue (iBALT) (16, 20–23). Notably, recent studies also suggest that the formation and function of iBALT can exhibit sex-specific differences, potentially influencing the progression and outcome of TB disease (24–27). Intriguingly, males are more susceptible than females according to global statistics. Sex hormones along with genetic factors, drive differences in immune responses between males and females, which may shape iBALT organization and its protective efficacy against Mtb infection (27). These findings suggest that B cells are not mere bystanders but central players in TB pathogenesis and protection, necessitating a reassessment of their role in shaping immune responses to Mtb infection, particularly in both sexes.
Historically, evaluating immune responses in TB, particularly the diversity and functional heterogeneity of B cells, their interactions with other immune cells, and their specific roles within the lungs—the primary site of infection—has been challenging. However, recent advancements in immunological techniques, including spatial transcriptomics and single-cell RNA sequencing, now allow for a more detailed characterization of the tissue microenvironment and the identification of distinct subsets of lung-resident B cells (14, 28, 29). This represents a new opportunity to unravel the role of B cells in localized immune response to Mtb infection; knowledge that will improve our understanding of the immune correlates of protection in TB and may inform the development of innovative therapeutic strategies. In this review we summarize these emerging insights, address current knowledge gaps and encourage deeper exploration into the diverse functions of B cells in TB immunity.
2 B cells and TB: what we know so far
Traditionally, B cells have been regarded as secondary players in the immune response to Mtb. However, over the past decade, numerous studies have challenged this view, revealing a potentially pivotal role for B cells in TB immunity (23, 30–33). During Mtb infection, B cells are reduced in peripheral blood and present within the granulomas in the lung (14, 32, 34–37), the hallmark structures of TB pathology. Moreover, B cells are well recognized for their canonical roles in immunity, such as antibody production (38); however, studies over the past decade have uncovered non-canonical functions of B cells that further expand their immunological significance (39). Through antigen presentation, cytokine production, and antibody secretion, B cells shape the local immune microenvironment and influence the dynamics of host-pathogen interactions (40, 41).
A particularly intriguing aspect of B cell activity in TB is their presence in TLS/iBALT. These structures emerge in response to chronic inflammation or infection and provide a localized lung environment where adaptive immunity is enhanced (42, 43). Here B cells also function as antigen-presenting cells (APCs), interacting with T cells to amplify immune responses (40, 44, 45). This underscores their importance in bridging humoral and cellular immunity to effectively combat Mtb.
A comprehensive understanding of both canonical and non-canonical roles is crucial to fully unravel the complexity of B cell-mediated immunity in TB. Here, we consolidate current knowledge on the diverse functions of B cells in TB and other infectious and non-infectious diseases, highlighting both established and emerging roles, with a focus on iBALT.
2.1 Canonical role of B cells
Antibodies can directly neutralize Mtb by binding to its surface antigens, thereby preventing bacterial adhesion to host cells and intracellular entry (30). Through opsonization, antibody-coated Mtb is internalized by macrophages via Fc receptor-mediated uptake, known as antibody-dependent cellular phagocytosis (ADCP), a process that promotes phagosome maturation and enhances bacterial clearance (46, 47). Studies have identified anti-lipoarabinomannan (LAM) antibodies as particularly effective in inhibiting Mtb growth within macrophages by enhancing opsonization and promoting phagosome maturation (48, 49). Moreover, these antibodies have been shown to promote bacterial clearance through complement activation (50, 51). Fc regions also induce antibody-dependent cellular cytotoxicity (ADCC) reactions through neutrophil and natural killer (NK) cell degranulation which eliminates infected cells and controls bacterial load (47). Additionally, antibodies against Mtb-secreted proteins, including Ag85, ESAT-6, and CFP-10, are thought to disrupt bacterial virulence mechanisms and enhance host defense. Intriguingly, individuals highly exposed to Mtb who did not develop classical latent TB infection (as defined by positive IFN-γ release assay or tuberculin skin test) exhibited Mtb-specific humoral immunity with enhanced avidity, a shift toward the IgG1 subclass, and distinct IgG Fc-glycosylation profiles, instead of the typical IFN-γ response (52). Importantly, differential Fc glycosylation was found to modulate Fc-mediated antibody activity, indicating its potential to directly impact Mtb control (30). Furthermore, the corresponding Fc receptors (FcRs) appear to shape the overall immune response to Mtb. Mice lacking activating FcRs develop more severe immunopathology and higher bacterial burdens, whereas mice deficient in the inhibitory FcR show reduced pathology (53). Collectively, these lines of evidence suggest that Fc-mediated antibody effector functions together with the expression of Fc receptors significantly contribute to the modulation of TB disease.
Despite these advances, the precise contribution of antibodies to protection against TB remains contentious. Passive transfer experiments have shown that antibodies can confer measurable protection in some settings (31, 54–56), yet other studies report minimal or no benefit, highlighting the complexity of humoral responses to Mtb (33, 57). The protective capacity of antibodies likely depends on multiple factors, including isotype, antigen specificity, and Fc receptor engagement. Recent developments in systems serology and high-throughput sequencing now enable detailed profiling of the TB-specific antibody repertoire, offering new insight into how distinct antibody subclasses and functions may contribute to protection.
2.2 Non-canonical role of B cells
While B cells are best known for their role in antibody-mediated immunity, they also perform several non-canonical, regulatory, or tissue-specific functions, which are increasingly recognized. Among these roles, cytokine production has emerged as a critical mechanism by which B cells shape both innate and adaptive responses. A specialized subset known as regulatory B cells (Bregs) is particularly enriched for IL-10 secretion, enabling these cells to suppress excessive inflammation and maintain immune homeostasis (58, 59). Bregs have been detected in the blood of individuals with active TB (58), and they are also present in the lungs of Mtb-infected mice, particularly during the chronic phase of infection (59). Recent findings indicate that the absence of B cell-derived IL-10 enhances resistance to TB, suggesting that B cell–specific IL-10 interferes with optimal infection control (24). B cells can also produce other immunoregulatory cytokines that may impact TB outcomes including IL-35, and IL-35/IL-20 co-producing B cells have been identified in TB (60). Complementing these observations, in vivo studies have shown that B cell derived IL-35 can suppress T cell responses, potentially undermining anti-Mtb immunity (61). Likewise, type I IFN producing B cells may contribute to impaired Mtb control by promoting macrophage polarization towards an anti-inflammatory phenotype (62). Conversely, Tbet expressing B cell can secrete IFN-γ, which is central to TB immunity, and marginal zone B cells secrete numerous cytokines in response to Mtb stimulation ex vivo, including TNF-a, IL-2 and GM-CSF (63). Although these cytokines play an important role in TB the relevance of their B cell source in vivo is not yet clear. Finally, Linge et al. also demonstrate that B cell-derived IL-6 production following Mtb infection exerts pleiotropic effects on both B and T cell function (64). Collectively, these findings indicate that cytokine-producing B cell subsets can exert both protective and potentially detrimental effects during Mtb infection, shaping the balance between host defense and pathogen persistence.
One of the most intriguing aspect of B cells in TB is their participation in the formation of iBALT, a type of TLS that develops in the lung (40). Unlike secondary lymphoid organs (SLOs) such as lymph nodes, spleen, tonsils, and Peyer’s patches, which are anatomically predetermined, TLS develop dynamically in response to localized immune challenges (65–67). These structures form directly at the site of Mtb infection, creating a highly specialized immune microenvironment that promotes antigen presentation, cytokine signaling, and the maintenance of immune memory (40).
3 Putative mechanisms underlying iBALT formation: role of inflammation, infection, and cytokines
Although the precise mechanisms underlying iBALT formation in TB remain undefined, data from other respiratory infections indicate that inflammation, antigenic stimulation, lymphotoxin (LT) signaling, cytokines, and chemokines are key drivers of its development (68–71). Pro-inflammatory cytokines such as interleukin-17 (IL-17), interleukin-6 (IL-6), and interleukin-22 (IL-22) promote immune-cell recruitment, stromal cell activation, and the clustering of B and T cells into organized aggregates (72, 73). In parallel, LTα/β-LTβR interactions between lymphoid tissue inducer-like cells (including B cells) and stromal cells help imprint a lymphoid organizer phenotype on local fibroblasts and endothelial cells. Chemokines including CXCL13, CXCL12, CCL21, and CCL19 then guide lymphocyte migration and compartmentalization, fostering the emergence of follicular-like zones within iBALT that resemble germinal centers (GCs) in SLOs and are predicted to support antigen-driven selection, affinity maturation, and memory B cell formation (70, 74, 75).
Importantly, these LT cytokine-chemokine networks represent only one part of a broader, heterogeneous landscape of iBALT-inducing mechanisms. Studies in influenza, Pneumocystis infection, and LPS-driven neonatal inflammation show that iBALT can arise through both lymphotoxin-dependent and lymphotoxin-independent routes, with different cell types (e.g., Th17 cells, γδ T cells, ILC3, dendritic cells, and activated B cells) acting as lymphoid tissue inducer (LTi)-like populations, and with additional contributions from IL-1 family cytokines, type I interferons, and TNF-family members beyond LTα/β (76, 77). Moreover, iBALT may form de novo or via remodeling of pre-existing peribronchial/perivascular leukocyte-stromal aggregates, and the relative contribution of these pathways is likely shaped by pathogen type, antigen load, age, and the chronicity of inflammation (74, 76). Thus, the model below should be viewed as one experimentally supported framework rather than a single, exclusive mechanism of iBALT formation (Figure 1).
Figure 1. Putative mechanism of iBALT formation in TB: 1) Mtb infection leads to chronic inflammation; 2) Persistent inflammation drives the release of pro-inflammatory cytokines, including TNF family members, IL-6, IL-17, and IL-22, which promote immune cell recruitment and tissue remodeling; 3) Inflammatory cytokines activate lung stromal cells, prompting them to function as lymphoid tissue organizer (LTo) cells by upregulating LTβR and VCAM expression on their surface. This transformation is critical for TLS formation; 4) Activated B cells express LTα/β, which binds to LTβR on stromal cells, initiating their function as lymphoid tissue inducer (LTi) cells and promoting lymphoid-like structures; 5) LTα/β-LTβR interactions drive the expression of CXCL13, CCL19, and CCL21, which recruit B cells, T cells, and dendritic cells (DCs) to the inflamed site, creating a localized immune niche; 6) Production of CCL19, CCL21, CXCL12, and CXCL13, ensures the persistence of inducible bronchus-associated lymphoid tissue (iBALT) and reinforces local immune response; 7) A positive feedback loop amplifies the secretion of these critical chemokines and cytokines, stabilizing the iBALT structure and supporting its function as a persistent immune hub; 8) iBALT structures may develop germinal center-like formations, where T and B cells interact, leading to the generation of high-affinity antibodies against Mtb antigens, enhancing immune defense against infection. The image was created using Biorender. Define in the legend: Lymphatic endothelial cells (LEC), High endothelial venules (HEV).
3.1 Initiation
A local inflammatory insult in the lung for example infection induces production of cytokines such as IL-6, IL-17 and IL-22. These signals activate perivascular/peribronchial stromal cells, which begin to express CCL21, VCAM-1 and LTβR. Circulating B cells expressing α4β1 integrin and membrane LTα/β are recruited to these sites and, through VCAM-integrin and LTα/β-LTβR interactions, start to imprint a lymphoid-organizer phenotype on the stromal cells, seeding early TLS aggregates.
3.2 Maturation
As the niche stabilizes, lymphatic endothelial cells (LEC) and high endothelial venules (HEV) are induced, enabling efficient entry and exit of lymphocytes. Activated stromal cells, follicular dendritic cell (FDC) precursors and fibroblasts secrete homeostatic chemokines CXCL13, CXCL12, CCL19 and CCL21, which attract CXCR5+ and CXCR4+ B cells and CCR7+ T cells, including T follicular helper cells (Tfh). This chemokine-guided influx and segregation of cells drives the emergence of distinct B cell follicles and T cell zones, giving the structure a secondary-lymphoid-organ like architecture.
3.3 Maintenance
In the mature TLS, ongoing antigen stimulation and cytokine/chemokine production establish a positive feedback loop. GC like B cell clusters, plasma cells, FDC networks and T cells are maintained within the structure, allowing sustained local antibody production and T cell help. Depending on the inflammatory context, similar stromal and cytokine circuits can also stabilize alternative TLS configurations, so this model represents one major pathway rather than the only mechanism by which TLS can form and persist.
4 Pathogenic versus protective iBALT
Depending on the context iBALT can be either protective or contribute to pathology. Perhaps the simplest example is in organ transplantation, where immune regulation by iBALT confers transplant success (78–80) but pro-inflammatory iBALT results in rejection (78). Similarly, iBALT is associated with protection in conditions where inflammation is required such as in response to infection (74), or it can exacerbate inflammation in response to self-antigens contributing to autoimmunity.
4.1 Protective iBALT
In most infectious contexts, iBALT is associated with protection (15, 20, 21, 25, 81–88). This is partly due to the production of high-affinity antibodies within iBALT, which neutralize pathogens and limit their spread. These responses are enhanced upon secondary exposure in the presence of iBALT (89, 90). In mice infected with influenza, iBALT was protective even in mice completely lacking secondary lymphoid organs (91). Conversely, NHP infants do not form iBALT, resulting in a lower antibody response and increased pulmonary damage (92). Additionally, iBALT has been associated with reduced inflammation in viral (82) and bacterial infections (83, 84).
Modified Vaccinia Ankara (MVA) and Pneumocystis infections highlight the significance of iBALT as a priming site against unrelated pathogens (85–87). In influenza models, local memory exhibits broader specificity compared to lymph node-selected memory (88). Additionally, iBALT has been linked to positive cancer outcomes (93–95). TLS have been shown to enhance CD4+ and CD8+ T cell responses in cancer patients (93), and the role of B cell-mediated priming of protective T cell responses is an active area of investigation in cancer immunotherapy. This parallels the protective responses observed in TB models, where iBALT formation is associated with antigen-specific CD4+ and CD8+ T cell responses (96) (Figure 2).
Figure 2. Description of protective vs pathogenic iBALT. Following the induction of iBALT, the local microenvironment can sway the response to be protective or pathogenic. In general, a protective response (blue) entails a specific response driven by PAMP/PRR signaling. This induces IFN-γ driven responses to clear the pathogen along with pathogen-specific antibodies, resulting in short-term inflammation. In contrast, a pathogenic response (red) is generally driven by DAMPs from local tissue damage accompanied by increased/prolonged IL-17, LTα, BAFF, ICOS-L, and auto-reactive antibodies. This leads to prolonged inflammation, eosinophilia, neutrophil influx, and autoimmune pathology. The image was created using Biorender.
4.2 Pathogenic iBALT
Induced hypersensitivity and persistent inflammation are often associated with detrimental iBALT formation. Continuous exposure to foreign substances, such as cigarette smoke, can induce lung inflammation, leading to chronic obstructive pulmonary disease (COPD). In this scenario, iBALT contributes to harmful inflammation associated with aging and inflammaging (97). Similarly, allergies involve persistent antigen stimulation, which can result in iBALT-associated immunopathology (98). Ongoing inflammation can also lead to a loss of tolerance and the development of autoimmune conditions such as Rheumatoid lung disease, Sjögren syndrome and pulmonary arterial hypertension (99). In these cases the sustained production of IL-17 and LT drives the formation of pathogenic iBALT (100). Consequently, elevated levels of BAFF, ICOS-L, and LTα drive B cell survival and auto-antibody production (75, 99, 101, 102), perpetuating the pro-inflammatory loop (Figure 2).
Respiratory syncytial virus (RSV) infection is a Th2 driven condition (103) where iBALT is linked to the disease (104). Interestingly, in Th2 and/or Th17 driven conditions (98, 105), allergies can further exacerbate RSV pathology (106). In graft versus host disease (GVHD), the recruitment of CXCR5+ Tfh and GC B cell worsens the disease (78), whereas recruitment of CXCR5+ Tregs reduces lung rejection (79). Notably, the recruitment of FoxP3+ Tregs into iBALT can prevent transplant rejection by inhibiting CD40 and CD28 signaling, and even permits multiple transplantations (80).
4.3 B cell heterogeneity as a driver of protective and pathogenic outcomes
Across infections, whether B cells are protective or pathogenic depends on which B cell subsets are engaged and the affinity/quality of the antibodies they produce. In well-organized GCs in lymph nodes, spleen, or iBALT, follicular and GC B cells undergo somatic hypermutation and stringent selection; high-affinity clones are positively selected into the memory and plasma-cell compartments, where they produce class-switched antibodies that efficiently neutralize pathogens and provide durable protection after infection or vaccination (107, 108). By contrast, extrafollicular plasmablasts and “atypical” or age-associated B cells often expand under conditions of high or persistent antigen load and strong inflammatory signals. In severe COVID-19, for example, dominant extrafollicular B cell responses are associated with robust but relatively low-mutation antibody production, lupus-like autoreactivity, and poor clinical outcomes, indicating how impaired affinity maturation can track with immunopathology (109). Bregs add another layer of complexity as IL-10/IL-35 producing Bregs can limit tissue damage in autoimmunity and some infections, but in chronic viral disease they may also suppress protective T cell responses and favor pathogen persistence (110, 111). In addition, as mentioned, marginal zone B cell, which are present in TB infected lung tissue (14), secrete many relevant cytokines following Mtb stimulation. Antibody quality then modulates these subset effects: high-affinity, strongly neutralizing antibodies from well-selected B cells are typically protective, whereas non- or sub-neutralizing antibodies generated by sub optimally selected B cells can form immune complexes or mediate antibody-dependent enhancement (ADE), as shown for dengue and other flaviviruses where intermediate titers of cross-reactive IgG can increase viral entry and drive severe disease via Fcγ-receptor–bearing myeloid cells (112).
Although detailed mechanistic data in TB are more limited, human and experimental studies already suggest a similar spectrum. B cell rich TLS/iBALT adjacent to granulomas contain GC-like B cells and Tfh cells and are often associated with better-organized lesions and evidence of local immune control, consistent with a protective role for well-selected, tissue-resident B cell responses and their antibodies (20, 113–115). Conversely, B cells can also promote granulomatous inflammation and lung damage in chronic murine TB, highlighting that dysregulated or chronically stimulated B cell compartments may tilt toward pathology (16). This protective versus pathologic balance likely depends not only on the presence of B cells, but also on how their activation is focused and selected within these local niches. This raises the possibility that Mtb actively perturbs B cell selection upstream of antigen specificity to limit adaptive immunity and/or drive inflammation and tissue destruction to enhance transmission. Several studies have shown that active TB leads to the expansion of antibodies targeting unrelated pathogens, including measles, RSV and tetanus (116, 117). The mechanism is unclear, but one intriguing possibility is the existence of superantigen-like immune modulation (118) by a TB derived product. This has been described for other bacterial pathogens and involves bacterial factors binding conserved immunoglobulin regions outside the complementarity determining regions (CDRs) to broadly engage BCRs and drive non-cognate activation, deletion, and repertoire distortion (119). Such broad BCR pressure could reshape the pool of B cells available for iBALT GC reactions and reduce the probability of generating high-affinity protective clones where they are needed most. However, while T cell-directed superantigen activity has been proposed in TB (118), no Mtb-derived B cell superantigen has been identified to date, and similar patterns of non-cognate B cell activation could also arise from alternative mechanisms such as innate receptor signaling and inflammatory cytokine milieus (120).
Taken together, these examples support a model in which (i) subset composition (GC vs extrafollicular vs regulatory vs tissue-resident B cells) and (ii) antibody affinity/function (neutralizing vs sub-neutralizing, pro-inflammatory Fc profiles) jointly determine whether B cell responses are net protective or pathogenic.
5 iBALT in TB
Accumulating evidence suggests a positive correlation between iBALT formation and improved control of Mtb and latent TB infection (LTBI) (81, 121, 122). The structural organization of iBALT facilitates close interactions between B cells, T cells, and APCs thereby promoting efficient antigen presentation and T cell priming. Specifically, B cells within iBALT can present Mtb antigens to CD4+ T cells, supporting their activation and differentiation into effector T cells that secrete IFN-γ and other cytokines essential for macrophage activation and bacterial clearance (40). This interaction between B cells and T cells within iBALT may significantly enhance immune efficacy, particularly in the early stages of Mtb infection when localized immune activation is critical for controlling bacterial replication (15, 40).
The formation of lymphoid follicles is observed not only in Mtb infection but also following mucosal vaccination, which confers superior protection against TB in animal models (22, 123–125). Non-human primate studies have shown that macaques vaccinated with MtbΔsigH demonstrate protective immunity, characterized by the absence of granulomas and the formation of iBALT, along with strong antigen-specific CD4+ and CD8+ T cell responses (22). Intriguingly, exposure to commensal gut bacteria confers protection to pneumonia in mice by priming ILC3 cells to migrate to the lung (126). ILC3s mediate an early protective role against Mtb infection by priming iBALT formation via IL-22 and IL-17 and thereby starting the CXCL13/CXCR5 cascade (127). Finally, oral exposure to non-tuberculous mycobacteria promotes iBALT formation in BCG vaccinated mice and subsequent protection (15). Similarly, delivery of Mtb antigen-primed dendritic cells (DCs) rapidly induced iBALT formation and near-sterilizing immunity in mice (128). Collectively, these findings highlight that the induction of local lymphoid structures and B cell responses at mucosal sites is a critical component of protective immunity against TB and represents a promising strategy for next-generation vaccines.
In humans, iBALT is linked to latency and containment of infection, whereas its absence is associated with active disease (81, 121). In NHP, the presence of iBALT is associated with protection (22, 129). Recently intravenous-BCG administration achieved complete protection in NHP, characterized by the distinct appearance of CD11c+ and CD3+ immune infiltrates, termed “microgranulomas”, which are associated with protection (96). A Th1/Th17 response also correlated with protection (130). An elevated TB-specific IgM response was observed in infected human lungs (14), and a robust IgM response was linked to protection in NHP (131). While B cell depletion had a modest effect on protection in this model, protection primarily relies on CD4 and CD8 immunity (132), again suggesting that iBALT may be an important mediator of protection.
While iBALT is generally associated with protective immunity in TB, it may also contribute to disease progression in certain cases (as described above), particularly when linked to chronic inflammation. A study by Chen et al. found B cells to enhance inflammation and host-detrimental immunopathology (16) by promoting Th1 responses while restricting anti-inflammatory IL-10. In the absence of B cells, mice survived Mtb infection significantly longer. Differences in study outcomes may be due, in part, to the use of different Mtb strains, as variations in pathogen characteristics—such as cell wall components and lipid moieties—can shape the host immune response and influence the balance between protective and harmful inflammation. Moreover, the formation and function of iBALT may be influenced by host factors such as genetic susceptibility, sex, age, or co-morbidities, all of which can impact the efficacy of the immune response. In particular, sex has been shown to have a profound impact on the immune system and may therefore significantly shape iBALT formation.
6 Sex differences in immunity and iBALT formation
Sex differences in the immune system arise from variations in the development, function, and regulation of diverse immune cell populations, shaping distinct responses in males and females. These differences are influenced by a combination of genetic, hormonal, and environmental factors and have implications for immunity, autoimmunity, and vaccine responses (133). The underlying reasons for sex differences in TB are not fully understood and were long thought to result from gender-related differences in exposure, behavior, and lifestyle (26, 27). The study of the role of biological sex in TB is relatively recent and is based, in part, on the observation that the male bias in TB incidence becomes apparent only after puberty (WHO report) —indirectly implicating sex hormones as potential key mediators of this sex difference. Indeed, growing experimental evidence supports a direct impact of biological sex on anti-TB immune responses. In particular, murine infection models, which allow the isolation of biological sex from gender-related confounders, consistently demonstrate increased susceptibility of males compared with females. Male mice exhibit significantly reduced survival following Mtb infection, and this phenotype is observed across different genetic backgrounds (e.g. C57BL/6 and BALB/c mice) and with two distinct Mtb strains (25, 134, 135). Non-castrated male mice exhibited significantly higher mortality rates and bacillary burdens compared with female and castrated male mice, supporting a role for testosterone in increased disease susceptibility (134). In addition, BCG-vaccinated female mice showed greater protection against TB than males in two mouse models (136, 137). Collectively, these results indicate that females develop superior protective immunity against Mtb compared with males. However, this is not to discount the contribution of non-biological factors to the increased risk of TB disease in human males, which is likely to be significant.
Males and females exhibit important sex-specific differences in the B cell compartment, including variations in B cell numbers, activation status, and antibody production. Females generally display higher B cell counts and mount stronger humoral immune responses, producing higher antibody levels following infection or vaccination (133). Consistent with this, recent studies suggest notable sex differences in the formation, structure, and function of iBALT. In COPD, the development of lymphoid follicles is more pronounced in female mice upon exposure to cigarette smoke (138). These differences were abolished with ovariectomy, suggesting that female sex hormones play a key role in lymphoid follicle development. While their exact role in COPD remains unclear, lymphoid follicles have been linked to severe disease progression (139). Notably, females appear to be more susceptible to developing COPD and exhibit increased expression of lymphoid follicles in the airways of COPD-affected lungs (138, 140). Similarly, in a model of collagen-induced arthritis (CIA), Dimitrijević et al. (2020) (141) observed sex differences in the generation of T follicular helper cells (Tfh), a subset of CD4+ T cells crucial for B cell responses and germinal center formation. Female rats, who are more susceptible to CIA, exhibited significantly higher frequencies of Tfh cells, resulting in stronger GC B cell formation, elevated antibody responses, and more severe disease progression compared to males (141). In contrast, Mtb infected female mice –who exhibit improved long-term control of Mtb infection compared to males– develop larger B cell follicles than their male counterparts (25). The smaller size of B cell follicles in males, which is associated with increased disease progression and higher mortality rates, underscores the protective role of B cell follicles in TB immunity. Several cytokines critical for the formation and maintenance of iBALT are upregulated in females compared to males across various diseases (Table 1). Importantly, cytokines essential for protective immunity in TB, such as IL-1α, IL-6, IL-23, and IL-17 (156–159) play a crucial role in the induction and formation of iBALT and are elevated in Mtb-infected females compared to males. More recently, Swanson et al. (2023) demonstrated a crucial role of antigen-specific B cells in the strategic localization of Tfh-like cells within iBALT to mediate Mtb control (40). According to Linge et al., iBALT structures in TB-susceptible mice were populated by B cells lacking TB antigen specificity, underscoring once again the critical role of antigen-specificity in mounting a protective iBALT-mediated immune response (160). However, the influence of the biological sex on the generation of Tfh cells and the close interaction with B cells in iBALT in TB has yet to be elucidated.
Table 1. Sex differences in iBALT formation.
In summary, sex-specific differences in iBALT formation (Figure 3) contribute to the generally more robust immune responses in females, which may play an important role in the defense against infections like TB, but also in the higher prevalence of certain autoimmune and inflammatory diseases in the female population.
Figure 3. Proposed model of sex differences in iBALT formation. Higher numbers of B cells and T cells, particularly CD4+ T cells, along with increased levels of cytokines involved in iBALT development, may promote greater recruitment of these cells in females compared to males, potentially resulting in larger iBALT structures. In addition, elevated IL-21 and IL-27 together with reduced IL-2 could enhance Tfh cell differentiation in females. Together, these mechanisms may contribute to sex-specific differences in immunity, autoimmunity, and vaccine responses. HEV - high endothelial venules. The image was created using Biorender.
7 Discussion and concluding remarks
B cells play a far more dynamic and essential role in TB immunity than previously appreciated. Their involvement in antigen presentation, cytokine secretion, and TLS formation suggests that they are integral to shaping local immune responses in the lung. The discovery of iBALT as a potential site of protective immune activation challenges the conventional T cell-centric view of TB immunity and highlights new opportunities for immunotherapeutic strategies. The dual nature of iBALT—as both a protective structure and a contributor to pathology—necessitates a nuanced understanding of its regulation. Notably, IL-10-producing regulatory B cells may play a pivotal role in modulating TB immunity. While some B cell subsets contribute to protective responses, IL-10-secreting B cells could suppress pro-inflammatory immune activation, potentially limiting excessive lung damage but also creating an immunoregulatory environment that favors persistent Mtb infection. The balance between protective and immunosuppressive B cell functions within iBALT may be critical in determining TB disease outcomes.
Building on the evidence summarized in this review, we propose that B cells and iBALT could advance TB vaccine development and immunotherapy through several mechanisms. iBALT forms a lung-resident, germinal center-like niche where B cells undergo antigen-driven selection, class switching, and affinity maturation at the site of Mtb infection, producing high-affinity IgA and IgG that opsonize bacilli, neutralize secreted factors, and engage Fc-mediated effector pathways. B cells also act as antigen-presenting cells and cytokine producers, shaping local Th1, Th17, and Tfh responses and granuloma organization. Next-generation TB vaccines could be designed to induce protective iBALT using mucosal delivery platforms, adjuvants that promote lymphoid neogenesis and CXCL13-dependent recruitment, and antigens efficiently captured and presented by B cells, thereby establishing long-lived, tissue-resident B and T cell immunity in the lung. In parallel, defining B cell antigenic specificities, isotypes, and functional profiles in controlled versus progressive disease can guide selection of Mtb antigens and antibody subclasses for monoclonal therapies to enhance clearance, shorten chemotherapy, or prevent reactivation. This strategy may also identify targets for host-directed interventions that modulate B cell or iBALT function to reinforce protective rather than pathological lung immunity.
Author contributions
TSD: Conceptualization, Funding acquisition, Supervision, Visualization, Writing – original draft, Writing – review & editing. DH: Conceptualization, Resources, Visualization, Writing – original draft, Writing – review & editing. RK: Conceptualization, Resources, Visualization, Writing – original draft, Writing – review & editing. MH-T: Writing – review & editing. AL: Writing – review & editing. BS: Resources, Writing – review & editing.
Funding
The author(s) declared that financial support was received for this work and/or its publication. TSD acknowledges funding support from the National Institute of Allergy and Infectious Diseases (NIAID), NIH through the K99/R00 Pathway to Independence Award (1K99AI173401-01), which has been instrumental in supporting her research on B cell-mediated immunity in tuberculosis. RK is thankful for grant from the UK Medical Research Foundation (MRF-131-0002-RG-ELKIC0850) and Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE) path to independence award #SANTHE-PTI007.
Acknowledgments
This review reflects a global collaboration among early career researchers from the USA, South Africa, and Germany. We are especially grateful to our mentors and colleagues who provided valuable insights during the development of this manuscript.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Global tuberculosis report (2025). Available online at: https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-reports/global-tuberculosis-report-2025 (Accessed December 11, 2025).
2. Zhuang L, Ye Z, Li L, Yang L, and Gong W. Next-generation TB vaccines: progress, challenges, and prospects. Vaccines. (2023) 11:1304. doi: 10.3390/vaccines11081304, PMID: 37631874
3. Sachdeva KS and Chadha VK. TB-vaccines: Current status & challenges. Indian J Med Res. (2024) 160:338–45. doi: 10.25259/IJMR_1478_2024, PMID: 39632643
4. Larsen SE, Williams BD, Rais M, Coler RN, and Baldwin SL. It takes a village: the multifaceted immune response to mycobacterium tuberculosis infection and vaccine-induced immunity. Front Immunol. (2022) 13:840225. doi: 10.3389/fimmu.2022.840225, PMID: 35359957
5. Nemes E, Fiore-Gartland A, Boggiano C, Coccia M, D’Souza P, Gilbert P, et al. The quest for vaccine-induced immune correlates of protection against tuberculosis. Vaccine Insights. (2022) 1:165–81. doi: 10.18609/vac/2022.027, PMID: 37091190
6. Behar SM. Antigen-specific CD8+ T cells and protective immunity to tuberculosis. Adv Exp Med Biol. (2013) 783:141–63. doi: 10.1007/978-1-4614-6111-1_8, PMID: 23468108
7. Lin PL, Rutledge T, Green AM, Bigbee M, Fuhrman C, Klein E, et al. CD4 T cell depletion exacerbates acute Mycobacterium tuberculosis while reactivation of latent infection is dependent on severity of tissue depletion in cynomolgus macaques. AIDS Res Hum Retroviruses. (2012) 28:1693–702. doi: 10.1089/AID.2012.0028, PMID: 22480184
8. Mpande CAM, Rozot V, Mosito B, Musvosvi M, Dintwe OB, Bilek N, et al. Immune profiling of Mycobacterium tuberculosis-specific T cells in recent and remote infection. eBioMedicine. (2021) 64:103233. doi: 10.1016/j.ebiom.2021.103233, PMID: 33610126
9. Urdahl KB, Shafiani S, and Ernst JD. Initiation and regulation of T-cell responses in tuberculosis. Mucosal Immunol. (2011) 4:288–93. doi: 10.1038/mi.2011.10, PMID: 21451503
10. Ogongo P, Porterfield JZ, and Leslie A. Lung tissue resident memory T-cells in the immune response to mycobacterium tuberculosis. Front Immunol. (2019) 10:992. doi: 10.3389/fimmu.2019.00992, PMID: 31130965
11. Flores-Gonzalez J, Urbán-Solano A, Ramón-Luing LA, Cancino-Diaz JC, Contreras-Rodriguez A, Curiel-Quesada E, et al. Active tuberculosis patients have high systemic IgG levels and B cells fingerprinting, characterized by a reduced capacity to produce IFN-γ or IL-10 as a response to M.tb antigens. Front Immunol. (2023) 14:1263458. doi: 10.3389/fimmu.2023.1263458, PMID: 38022616
12. Dutt TS and Choreño-Parra JA. Editorial: Tuberculosis and humoral immunity. Front Immunol. (2025) 16:1562567. doi: 10.3389/fimmu.2025.1562567, PMID: 39995662
13. Wang Q, Nag D, Baldwin SL, Coler RN, and McNamara RP. Antibodies as key mediators of protection against Mycobacterium tuberculosis. Front Immunol. (2024) 15:1430955. doi: 10.3389/fimmu.2024.1430955, PMID: 39286260
14. Krause R, Ogongo P, Tezera L, Ahmed M, Mbano I, Chambers M, et al. B cell heterogeneity in human tuberculosis highlights compartment-specific phenotype and functional roles. Commun Biol. (2024) 7:1–15. doi: 10.1038/s42003-024-06282-7, PMID: 38755239
15. Dutt TS, Karger BR, Fox A, Youssef N, Dadhwal R, Ali MZ, et al. Mucosal exposure to non-tuberculous mycobacteria elicits B cell-mediated immunity against pulmonary tuberculosis. Cell Rep. (2022) 41:111783. doi: 10.1016/j.celrep.2022.111783, PMID: 36516760
16. Chen Y, Bharrhan S, Xu J, Sharma T, Wang Y, Salgame P, et al. B cells promote granulomatous inflammation during chronic Mycobacterium tuberculosis infection in mice. PloS Pathog. (2023) 19:e1011187. doi: 10.1371/journal.ppat.1011187, PMID: 36888692
17. Batista FD and Harwood NE. The who, how and where of antigen presentation to B cells. Nat Rev Immunol. (2009) 9:15–27. doi: 10.1038/nri2454, PMID: 19079135
18. Lund FE. Cytokine-producing B lymphocytes – key regulators of immunity. Curr Opin Immunol. (2008) 20:332–8. doi: 10.1016/j.coi.2008.03.003, PMID: 18417336
19. Vazquez MI, Catalan-Dibene J, and Zlotnik A. B cells responses and cytokine production are regulated by their immune microenvironment. Cytokine. (2015) 74:318–26. doi: 10.1016/j.cyto.2015.02.007, PMID: 25742773
20. Dunlap MD, Prince OA, Rangel-Moreno J, Thomas KA, Scordo JM, Torrelles JB, et al. Formation of lung inducible bronchus associated lymphoid tissue is regulated by mycobacterium tuberculosis expressed determinants. Front Immunol. (2020) 11:1325. doi: 10.3389/fimmu.2020.01325, PMID: 32695111
21. Nagatake T, Wada Y, Matsumoto N, Shimojou M, Hirata S, Nasu A, et al. Inducible bronchus-associated lymphoid tissue plays an important role in the induction of antigen-specific immune response by Ag85B-hPIV2-based anti-tuberculosis vaccine in mice. J Immunol. (2016) 196:68. doi: 10.4049/jimmunol.196.Supp.68.9
22. Kaushal D, Foreman TW, Gautam US, Alvarez X, Adekambi T, Rangel-Moreno J, et al. Mucosal vaccination with attenuated Mycobacterium tuberculosis induces strong central memory responses and protects against tuberculosis. Nat Commun. (2015) 6:8533. doi: 10.1038/ncomms9533, PMID: 26460802
23. Maglione PJ, Xu J, and Chan J. B Cells Moderate Inflammatory Progression and Enhance Bacterial Containment upon Pulmonary Challenge with Mycobacterium tuberculosis1. J Immunol. (2007) 178:7222–34. doi: 10.4049/jimmunol.178.11.7222, PMID: 17513771
24. Hertz D, Marwitz S, Eggers L, von Borstel L, Harikumar Parvathy G, Behrends J, et al. Sex-specific impact of B cell-derived IL-10 on tuberculosis resistance. Front Immunol. (2025) 16:1524500. doi: 10.3389/fimmu.2025.1524500, PMID: 40260245
25. Hertz D, Dibbern J, Eggers L, von Borstel L, and Schneider BE. Increased male susceptibility to Mycobacterium tuberculosis infection is associated with smaller B cell follicles in the lungs. Sci Rep. (2020) 10:5142. doi: 10.1038/s41598-020-61503-3, PMID: 32198367
26. Hertz D and Schneider B. Sex differences in tuberculosis. Semin Immunopathol. (2019) 41:225–37. doi: 10.1007/s00281-018-0725-6, PMID: 30361803
27. Gupta M, Srikrishna G, Klein S, and Bishai WR. Genetic and hormonal mechanisms underlying sex-specific immune responses in tuberculosis. Trends Immunol. (2022) 43:640–56. doi: 10.1016/j.it.2022.06.004, PMID: 35842266
28. Lee RD, Munro SA, Knutson TP, LaRue RS, Heltemes-Harris LM, and Farrar MA. Single-cell analysis identifies dynamic gene expression networks that govern B cell development and transformation. Nat Commun. (2021) 12:6843. doi: 10.1038/s41467-021-27232-5, PMID: 34824268
29. Hao D, Han G, Sinjab A, Gomez-Bolanos LI, Lazcano R, Serrano A, et al. The single-cell immunogenomic landscape of B and plasma cells in early-stage lung adenocarcinoma. Cancer Discov. (2022) 12:2626–45. doi: 10.1158/2159-8290.CD-21-1658, PMID: 36098652
30. Lu LL, Chung AW, Rosebrock TR, Ghebremichael M, Yu WH, Grace PS, et al. A functional role for antibodies in tuberculosis. Cell. (2016) 167:433–443.e14. doi: 10.1016/j.cell.2016.08.072, PMID: 27667685
31. Kawahara JY, Irvine EB, and Alter G. A case for antibodies as mechanistic correlates of immunity in tuberculosis. Front Immunol. (2019) 10:996. doi: 10.3389/fimmu.2019.00996, PMID: 31143177
32. Phuah JY, Mattila JT, Lin PL, and Flynn JL. Activated B cells in the granulomas of nonhuman primates infected with Mycobacterium tuberculosis. Am J Pathol. (2012) 181:508–14. doi: 10.1016/j.ajpath.2012.05.009, PMID: 22721647
33. Spatola M, Nziza N, Irvine EB, Cizmeci D, Jung W, Van LH, et al. Distinctive antibody responses to Mycobacterium tuberculosis in pulmonary and brain infection. Brain. (2024) 147:3247–60. doi: 10.1093/brain/awae066, PMID: 38442687
34. Joosten SA, van MKE, del NF, Baiocchini A, Petrone L, Vanini V, et al. Patients with tuberculosis have a dysfunctional circulating B cells compartment, which normalizes following successful treatment. PloS Pathog. (2016) 12:e1005687. doi: 10.1371/journal.ppat.1005687, PMID: 27304615
35. Corominas M, Cardona V, Gonzalez L, Caylà JA, Rufi G, Mestre M, et al. B-lymphocytes and co-stimulatory molecules in Mycobacterium tuberculosis infection. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. (2004) 8:98–105., PMID: 14974752
36. Hernandez J, Velazquez C, Valenzuela O, Robles-Zepeda R, Ruiz-Bustos E, Navarro M, et al. Low number of peripheral blood B lymphocytes in patients with pulmonary tuberculosis. Immunol Invest. (2010) 39:197–205. doi: 10.3109/08820130903586346, PMID: 20380518
37. Roy Chowdhury R, Vallania F, Yang Q, Lopez Angel CJ, Darboe F, Penn-Nicholson A, et al. A multi-cohort study of the immune factors associated with M. tuberculosis infection outcomes. Nat. (2018) 560:644–8. doi: 10.1038/s41586-018-0439-x, PMID: 30135583
38. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, and Walter P. B cells and antibodies. In: Molecular biology of the cell (2002). New York, London: Garland Science. Available online at: https://www.ncbi.nlm.nih.gov/books/NBK26884/. Garland Science.
39. Haas KM. Non-canonical B cells: characteristics of uncharacteristic B cells. J Immunol Baltim Md. (2023) 1950:211. doi: 10.4049/jimmunol.2200944, PMID: 37844278
40. Swanson RV, Gupta A, Foreman TW, Lu L, Choreno-Parra JA, Mbandi SK, et al. Antigen-specific B cells direct T follicular-like helper cells into lymphoid follicles to mediate Mycobacterium tuberculosis control. Nat Immunol. (2023) 24:855–68. doi: 10.1038/s41590-023-01476-3, PMID: 37012543
41. Akkaya M, Kwak K, and Pierce SK. B cell memory: building two walls of protection against pathogens. Nat Rev Immunol. (2020) 20:229–38. doi: 10.1038/s41577-019-0244-2, PMID: 31836872
42. Onodera T, Takahashi Y, Yokoi Y, Ato M, Kodama Y, Hachimura S, et al. Memory B cells in the lung participate in protective humoral immune responses to pulmonary influenza virus reinfection. Proc Natl Acad Sci. (2012) 109:2485–90. doi: 10.1073/pnas.1115369109, PMID: 22308386
43. Germain C, Gnjatic S, Tamzalit F, Knockaert S, Remark R, Goc J, et al. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am J Respir Crit Care Med. (2014) 189:832–44. doi: 10.1164/rccm.201309-1611OC, PMID: 24484236
44. Hughes CE, Benson RA, Bedaj M, and Maffia P. Antigen-presenting cells and antigen presentation in tertiary lymphoid organs. Front Immunol. (2016) 7:481. doi: 10.3389/fimmu.2016.00481, PMID: 27872626
45. Naderi W, Schreiner D, and King CG. T-cell-B cells collaboration in the lung. Curr Opin Immunol. (2023) 81:102284. doi: 10.1016/j.coi.2023.102284, PMID: 36753826
46. Lu LL, Suscovich TJ, Fortune SM, and Alter G. Beyond binding: antibody effector functions in infectious diseases. Nat Rev Immunol. (2018) 18:46–61. doi: 10.1038/nri.2017.106, PMID: 29063907
47. Irvine EB, Nikolov A, Khan MZ, Peters JM, Lu R, Sixsmith J, et al. Fc-engineered antibodies promote neutrophil-dependent control of Mycobacterium tuberculosis. Nat Microbiol. (2024) 9:2369–82. doi: 10.1038/s41564-024-01777-9, PMID: 39174703
48. Kang PB, Azad AK, Torrelles JB, Kaufman TM, Beharka A, Tibesar E, et al. The human macrophage mannose receptor directs Mycobacterium tuberculosis lipoarabinomannan-mediated phagosome biogenesis. J Exp Med. (2005) 202:987–99. doi: 10.1084/jem.20051239, PMID: 16203868
49. Kumar SK, Singh P, and Sinha S. Naturally produced opsonizing antibodies restrict the survival of Mycobacterium tuberculosis in human macrophages by augmenting phagosome maturation. Open Biol. (2015) 5:150171. doi: 10.1098/rsob.150171, PMID: 26674415
50. Correia-Neves M, Sundling C, Cooper A, and Källenius G. Lipoarabinomannan in active and passive protection against tuberculosis. Front Immunol. (2019) 10:1968. doi: 10.3389/fimmu.2019.01968, PMID: 31572351
51. Ishida E, Corrigan DT, Malonis RJ, Hofmann D, Chen T, Amin AG, et al. Monoclonal antibodies from humans with Mycobacterium tuberculosis exposure or latent infection recognize distinct arabinomannan epitopes. Commun Biol. (2021) 4:1–13. doi: 10.1038/s42003-021-02714-w, PMID: 34642445
52. Lu LL, Smith MT, Yu KKQ, Luedemann C, Suscovich TJ, Grace PS, et al. IFN-γ-independent immune markers of Mycobacterium tuberculosis exposure. Nat Med. (2019) 25:977–87. doi: 10.1038/s41591-019-0441-3, PMID: 31110348
53. Maglione PJ, Xu J, Casadevall A, and Chan J. Fc gamma receptors regulate immune activation and susceptibility during Mycobacterium tuberculosis infection. J Immunol Baltim Md 1950. (2008) 180:3329–38. doi: 10.4049/jimmunol.180.5.3329, PMID: 18292558
54. Williams A, Reljic R, Naylor I, Clark SO, Falero-Diaz G, Singh M, et al. Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs. Immunology. (2004) 111:328–33. doi: 10.1111/j.1365-2567.2004.01809.x, PMID: 15009434
55. Glatman-Freedman A and Casadevall A. Serum Therapy for Tuberculosis Revisited: Reappraisal of the Role of Antibody-Mediated Immunity against Mycobacterium tuberculosis. Clin Microbiol Rev. (1998) 11:514–32. doi: 10.1128/CMR.11.3.514, PMID: 9665981
56. Guirado E, Amat I, Gil O, Díaz J, Arcos V, Caceres N, et al. Passive serum therapy with polyclonal antibodies against Mycobacterium tuberculosis protects against post-chemotherapy relapse of tuberculosis infection in SCID mice. Microbes Infect. (2006) 8:1252–9. doi: 10.1016/j.micinf.2005.12.004, PMID: 16702016
57. McLean MR, Lu LL, Kent SJ, and Chung AW. An inflammatory story: antibodies in tuberculosis comorbidities. Front Immunol. (2019) 10:2846. doi: 10.3389/fimmu.2019.02846, PMID: 31921122
58. Yuan C, Qu Z-L, Tang X-L, Liu Q, Luo W, Huang C, et al. Mycobacterium tuberculosis mannose-capped lipoarabinomannan induces IL-10-producing B cells and hinders CD4+Th1 immunity. iScience. (2019) 11:13–30. doi: 10.1016/j.isci.2018.11.039, PMID: 30572206
59. Moreira-Teixeira L, Redford PS, Stavropoulos E, Ghilardi N, Maynard CL, Weaver CT, et al. O’Garra A. T cell-derived IL-10 impairs host resistance to mycobacterium tuberculosis infection. J Immunol Baltim Md. (2017) 1950:199. doi: 10.4049/jimmunol.1601340, PMID: 28584007
60. Dai Y-C, Wang W-D, Zhang J-A, Chen C, Luo H-L, Xu H, et al. MTB driven B cells producing IL-35 and secreting high level of IL-10 in the patients with active pulmonary tuberculosis. Mol Immunol. (2019) 112:175–81. doi: 10.1016/j.molimm.2019.05.004, PMID: 31170628
61. Chen C, Xu H, Peng Y, Luo H, Huang G-X, Wu X-J, et al. Elevation in the counts of IL-35-producing B cells infiltrating into lung tissue in mycobacterial infection is associated with the downregulation of Th1/Th17 and upregulation of Foxp3+Treg. Sci Rep. (2020) 10:13212. doi: 10.1038/s41598-020-69984-y, PMID: 32764544
62. Bénard A, Sakwa I, Schierloh P, Colom A, Mercier I, Tailleux L, et al. B cells producing type I IFN modulate macrophage polarization in tuberculosis. Am J Respir Crit Care Med. (2018) 197:801–13. doi: 10.1164/rccm.201707-1475OC, PMID: 29161093
63. Tsai C-Y, Oo M, Peh JH, Yeo BCM, Aptekmann A, Lee B, et al. Splenic marginal zone B cells restrict Mycobacterium tuberculosis infection by shaping the cytokine pattern and cell-mediated immunity. Cell Rep. (2024) 43:114426. doi: 10.1016/j.celrep.2024.114426, PMID: 38959109
64. Linge I, Tsareva A, Kondratieva E, Dyatlov A, Hidalgo J, Zvartsev R, et al. Pleiotropic effect of IL-6 produced by B-lymphocytes during early phases of adaptive immune responses against TB infection. Front Immunol. (2022) 13:750068. doi: 10.3389/fimmu.2022.750068, PMID: 35154093
65. Chen Y, Wu Y, Yan G, and Zhang G. Tertiary lymphoid structures in cancer: maturation and induction. Front Immunol. (2024) 15:1369626. doi: 10.3389/fimmu.2024.1369626, PMID: 38690273
66. Zhao L, Jin S, Wang S, Zhang Z, Wang X, Chen Z, et al. Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances. Signal Transduct Target Ther. (2024) 9:1–43. doi: 10.1038/s41392-024-01947-5, PMID: 39198425
67. Khanal S, Wieland A, and Gunderson AJ. Mechanisms of tertiary lymphoid structure formation: cooperation between inflammation and antigenicity. Front Immunol. (2023) 14:1267654. doi: 10.3389/fimmu.2023.1267654, PMID: 37809103
68. Gao X, Liu C, and Wang S. Mucosal immune responses in the lung during respiratory infection: The organization and regulation of iBALT structure. hLife. (2023) 1:71–82. doi: 10.1016/j.hlife.2023.09.001
69. Inducible bronchus-associated lymphoid tissue: taming inflammation in the lung - pubMed. Available online at (Accessed December 11, 2025).
70. Tan H-X, Esterbauer R, Vanderven HA, Juno JA, Kent SJ, and Wheatley AK. Inducible bronchus-associated lymphoid tissues (iBALT) serve as sites of B cell selection and maturation following influenza infection in mice. Front Immunol. (2019) 10:611. doi: 10.3389/fimmu.2019.00611, PMID: 30984186
71. Foo SY and Phipps S. Regulation of inducible BALT formation and contribution to immunity and pathology. Mucosal Immunol. (2010) 3:537–44. doi: 10.1038/mi.2010.52, PMID: 20811344
72. Eddens T, Elsegeiny W, Garcia-Hernadez M de la L, Castillo P, Trevejo-Nunez G, Serody K, et al. Pneumocystis-driven inducible bronchus-associated lymphoid tissue formation requires th2 and th17 immunity. . Cell Rep. (2017) 18:3078–90. doi: 10.1016/j.celrep.2017.03.016, PMID: 28355561
73. Rangel-Moreno J, Carragher DM, de la Luz Garcia-Hernandez M, Hwang JY, Kusser K, Hartson L, et al. The development of inducible bronchus-associated lymphoid tissue depends on IL-17. Nat Immunol. (2011) 12:639–46. doi: 10.1038/ni.2053, PMID: 21666689
74. Silva-Sanchez A and Randall TD. Role of iBALT in respiratory immunity. Curr Top Microbiol Immunol. (2020) 426:21–43. doi: 10.1007/82_2019_191, PMID: 31974759
75. Rangel-Moreno J, Hartson L, Navarro C, Gaxiola M, Selman M, and Randall TD. Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest. (2006) 116:3183–94. doi: 10.1172/JCI28756, PMID: 17143328
76. Zhao R and Gao D. Innate immunity and tertiary lymphoid structures. Immunol Rev. (2025) 332:e70052. doi: 10.1111/imr.70052, PMID: 40600919
77. Nagatake T, Suzuki H, Hirata S, Matsumoto N, Wada Y, Morimoto S, et al. Immunological association of inducible bronchus-associated lymphoid tissue organogenesis in Ag85B-rHPIV2 vaccine-induced anti-tuberculosis mucosal immune responses in mice. Int Immunol. (2018) 30:471–81. doi: 10.1093/intimm/dxy046, PMID: 30011025
78. Flynn R, Du J, Veenstra RG, Reichenbach DK, Panoskaltsis-Mortari A, Taylor PA, et al. Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood. (2014) 123:3988–98. doi: 10.1182/blood-2014-03-562231, PMID: 24820310
79. McDonald-Hyman C, Flynn R, Panoskaltsis-Mortari A, Peterson N, MacDonald KPA, Hill GR, et al. Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner. Blood. (2016) 128:1013–7. doi: 10.1182/blood-2016-05-715896, PMID: 27385791
80. Li W, Gauthier JM, Higashikubo R, Hsiao H-M, Tanaka S, Vuong L, et al. Bronchus-associated lymphoid tissue–resident Foxp3+ T lymphocytes prevent antibody-mediated lung rejection. J Clin Invest. (2019) 129:556–68. doi: 10.1172/JCI122083, PMID: 30561386
81. Zhang M, Wang Z, Graner MW, Yang L, Liao M, Yang Q, et al. B cell infiltration is associated with the increased IL-17 and IL-22 expression in the lungs of patients with tuberculosis. Cell Immunol. (2011) 270:217–23. doi: 10.1016/j.cellimm.2011.05.009, PMID: 21741035
82. Moyron-Quiroz JE, Rangel-Moreno J, Kusser K, Hartson L, Sprague F, Goodrich S, et al. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat Med. (2004) 10:927–34. doi: 10.1038/nm1091, PMID: 15311275
83. Iwata M and Sato A. Morphological and immunohistochemical studies of the lungs and bronchus-associated lymphoid tissue in a rat model of chronic pulmonary infection with Pseudomonas aeruginosa. Infect Immun. (1991) 59:1514–20. doi: 10.1128/iai.59.4.1514-1520.1991, PMID: 2004830
84. Kitazawa H, Sato A, and Iwata M. A study of bronchus-associated lymphoid tissue in a rat model of chronic pulmonary infection with pseudomonas aeruginosa. J Jpn Assoc Infect Dis. (1997) 71:214–21. doi: 10.11150/kansenshogakuzasshi1970.71.214, PMID: 9128005
85. Halle S, Dujardin HC, Bakocevic N, Fleige H, Danzer H, Willenzon S, et al. Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells. J Exp Med. (2009) 206:2593–601. doi: 10.1084/jem.20091472, PMID: 19917776
86. Swain SD, Meissner N, Han S, and Harmsen A. Pneumocystis infection in an immunocompetent host can promote collateral sensitization to respiratory antigens. Infect Immun. (2011) 79:1905–14. doi: 10.1128/iai.01273-10, PMID: 21343358
87. Wiley JA and Harmsen AG. Pneumocystis infection enhances antibody-mediated resistance to a subsequent influenza infection1. J Immunol. (2008) 180:5613–24. doi: 10.4049/jimmunol.180.8.5613, PMID: 18390746
88. Adachi Y, Onodera T, Yamada Y, Daio R, Tsuiji M, Inoue T, et al. Distinct germinal center selection at local sites shapes memory B cell response to viral escape. J Exp Med. (2015) 212:1709–23. doi: 10.1084/jem.20142284, PMID: 26324444
89. Rangel-Moreno J, Carragher DM, Garcia-Hernandez M de la L, Hwang JY, Kusser K, Hartson L, et al. The development of inducible Bronchus Associated Lymphoid Tissue (iBALT) is dependent on IL-17. . Nat Immunol. (2011) 12:639–46. doi: 10.1038/ni.2053, PMID: 21666689
90. Wiley JA, Richert LE, Swain SD, Harmsen A, Barnard DL, Randall TD, et al. Inducible bronchus-associated lymphoid tissue elicited by a protein cage nanoparticle enhances protection in mice against diverse respiratory viruses. PloS One. (2009) 4:e7142. doi: 10.1371/journal.pone.0007142, PMID: 19774076
91. Moyron-Quiroz JE, Rangel-Moreno J, Hartson L, Kusser K, Tighe MP, Klonowski KD, et al. Persistence and responsiveness of immunologic memory in the absence of secondary lymphoid organs. Immunity. (2006) 25:643–54. doi: 10.1016/j.immuni.2006.08.022, PMID: 17045819
92. Holbrook BC, Hayward SL, Blevins LK, Kock N, Aycock T, Parks GD, et al. Nonhuman primate infants have an impaired respiratory but not systemic IgG antibody response following influenza virus infection. Virology. (2015) 476:124–33. doi: 10.1016/j.virol.2014.12.007, PMID: 25543963
93. Tamiya Y, Nakai T, Suzuki A, Mimaki S, Tsuchihara K, Sato K, et al. The impact of tertiary lymphoid structures on clinicopathological, genetic and gene expression characteristics in lung adenocarcinoma. Lung Cancer Amst Neth. (2022) 174:125–32. doi: 10.1016/j.lungcan.2022.11.001, PMID: 36379125
94. Kasikova L, Rakova J, Hensler M, Lanickova T, Tomankova J, Pasulka J, et al. Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer. Nat Commun. (2024) 15:2528. doi: 10.1038/s41467-024-46873-w, PMID: 38514660
95. Rodriguez AB, Peske JD, Woods AN, Leick KM, Mauldin IS, Meneveau MO, et al. Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. Cell Rep. (2021) 36(3):109422. doi: 10.1016/j.celrep.2021.109422, PMID: 34289373
96. Singh DK, Ahmed M, Akter S, Shivanna V, Bucşan AN, Mishra A, et al. Prevention of tuberculosis in cynomolgus macaques by an attenuated Mycobacterium tuberculosis vaccine candidate. Nat Commun. (2025) 16:1957. doi: 10.1038/s41467-025-57090-4, PMID: 40000643
97. John-Schuster G, Günter S, Hager K, Conlon TM, Eickelberg O, and Yildirim AÖ. Inflammaging increases susceptibility to cigarette smoke-induced COPD. Oncotarget. (2016) 7:30068–83. doi: 10.18632/oncotarget.4027, PMID: 26284585
98. Shinoda K, Hirahara K, and Nakayama T. Maintenance of pathogenic Th2 cells in allergic disorders. Allergol Int. (2017) 66:369–76. doi: 10.1016/j.alit.2017.03.005, PMID: 28391979
99. Perros F, Dorfmüller P, Montani D, Hammad H, Waelput W, Girerd B, et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. (2012) 185:311–21. doi: 10.1164/rccm.201105-0927OC, PMID: 22108206
100. Gopal R, Rangel-Moreno J, Junecko BAF, Mallon DJ, Chen K, Pociask DA, et al. Mucosal pre-exposure to th17-inducing adjuvants exacerbates pathology after influenza infection. Am J Pathol. (2014) 184:55–63. doi: 10.1016/j.ajpath.2013.09.012, PMID: 24183780
101. Gosman MME, Willemse BWM, Jansen DF, Lapperre TS, van SA, PS H, et al. Group the G and LUC in OLD (GLUCOLD) S. Increased number of B cellss in bronchial biopsies in COPD. Eur Respir J. (2006) 27:60–4. doi: 10.1183/09031936.06.00007005, PMID: 16387936
102. Colvin KL, Cripe PJ, Ivy DD, Stenmark KR, and Yeager ME. Bronchus-associated lymphoid tissue in pulmonary hypertension produces pathologic autoantibodies. Am J Respir Crit Care Med. (2013) 188:1126–36. doi: 10.1164/rccm.201302-0403OC, PMID: 24093638
103. Auais A, Adkins B, Napchan G, and Piedimonte G. Immunomodulatory effects of sensory nerves during respiratory syncytial virus infection in rats. Am J Physiol-Lung Cell Mol Physiol. (2003) 285:L105–13. doi: 10.1152/ajplung.00004.2003, PMID: 12639840
104. Johnson JE, Gonzales RA, Olson SJ, Wright PF, and Graham BS. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol. (2007) 20:108–19. doi: 10.1038/modpathol.3800725, PMID: 17143259
105. Holt PG and Sly PD. Th2 cytokines in the asthma late-phase response. Lancet. (2007) 370:1396–8. doi: 10.1016/S0140-6736(07)61587-6, PMID: 17950849
106. Robinson PJ, Hegele RG, and Schellenberg RR. Allergic sensitization increases airway reactivity in Guinea pigs with respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol. (1997) 100:492–8. doi: 10.1016/S0091-6749(97)70141-6, PMID: 9338543
107. Mesin L, Ersching J, and Victora GD. Germinal center B cell dynamics. Immunity. (2016) 45:471–82. doi: 10.1016/j.immuni.2016.09.001, PMID: 27653600
108. Maglione PJ and Chan J. How B cells shape the immune response against Mycobacterium tuberculosis. Eur J Immunol. (2009) 39:676–86. doi: 10.1002/eji.200839148, PMID: 19283721
109. Woodruff MC, Ramonell RP, Nguyen DC, Cashman KS, Saini AS, Haddad NS, et al. Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nat Immunol. (2020) 21:1506–16. doi: 10.1038/s41590-020-00814-z, PMID: 33028979
110. Menon M, Hussell T, and Ali Shuwa H. Regulatory B cells in respiratory health and diseases. Immunol Rev. (2021) 299:61–73. doi: 10.1111/imr.12941, PMID: 33410165
111. Mauri C and Menon M. Human regulatory B cells in health and disease: therapeutic potential. J Clin Invest. (2017) 127:772–9. doi: 10.1172/JCI85113, PMID: 28248202
112. Teo A, Tan HD, Loy T, Chia PY, and Chua CLL. Understanding antibody-dependent enhancement in dengue: Are afucosylated IgG1s a concern? PloS Pathog. (2023) 19:e1011223. doi: 10.1371/journal.ppat.1011223, PMID: 36996026
113. Chan J, Mehta S, Bharrhan S, Chen Y, Achkar JM, Casadevall A, et al. The role of B cells and humoral immunity in Mycobacterium tuberculosis infection. Semin Immunol. (2014) 26:588–600. doi: 10.1016/j.smim.2014.10.005, PMID: 25458990
114. Kozakiewicz L, Phuah J, Flynn J, and Chan J. The role of B cells and humoral immunity in mycobacterium tuberculosis infection. Adv Exp Med Biol. (2013) 783:225–50. doi: 10.1007/978-1-4614-6111-1_12, PMID: 23468112
115. Kahnert A, Höpken UE, Stein M, Bandermann S, Lipp M, and Kaufmann SHE. Mycobacterium tuberculosis triggers formation of lymphoid structure in murine lungs. J Infect Dis. (2007) 195:46–54. doi: 10.1086/508894, PMID: 17152008
116. Peralta Alvarez MP, Jones H, Redondo Azema H, Davis C, White AD, Sarfas C, et al. Low-dose M.tb infection but not BCG or MTBVAC vaccination enhances heterologous antibody titres in non-human primates. Front Immunol. (2024) 15:1387454. doi: 10.3389/fimmu.2024.1387454, PMID: 38799468
117. Kimuda SG, Andia-Biraro I, Sebina I, Egesa M, Nalwoga A, Smith SG, et al. Mycobacterium tuberculosis infection is associated with increased B cell responses to unrelated pathogens. Sci Rep. (2020) 10:14324. doi: 10.1038/s41598-020-71044-4, PMID: 32868810
118. Ohmen JD, Barnes PF, Grisso CL, Bloom BR, and Modlin RL. Evidence for a superantigen in human tuberculosis. Immunity. (1994) 1:35–43. doi: 10.1016/1074-7613(94)90007-8, PMID: 7889397
119. Levinson AI, Kozlowski L, Zheng Y, and Wheatley L. B cells superantigens: definition and potential impact on the immune response. J Clin Immunol. (1995) 15:26S–36S. doi: 10.1007/BF01540891, PMID: 8613489
120. Bernasconi NL, Traggiai E, and Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science. (2002) 298:2199–202. doi: 10.1126/science.1076071, PMID: 12481138
121. Ulrichs T, Kosmiadi GA, Jörg S, Pradl L, Titukhina M, Mishenko V, et al. Differential organization of the local immune response in patients with active cavitary tuberculosis or with nonprogressive tuberculoma. J Infect Dis. (2005) 192:89–97. doi: 10.1086/430621, PMID: 15942898
122. Ulrichs T, Kosmiadi GA, Trusov V, Jörg S, Pradl L, Titukhina M, et al. Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung. J Pathol. (2004) 204:217–28. doi: 10.1002/path.1628, PMID: 15376257
123. Perdomo C, Zedler U, Kühl AA, Lozza L, Saikali P, Sander LE, et al. Mucosal BCG vaccination induces protective lung-resident memory T cell populations against tuberculosis. mBio. (2016) 7:10. doi: 10.1128/mbio.01686-16, PMID: 27879332
124. Aguilo N, Alvarez-Arguedas S, Uranga S, Marinova D, Monzón M, Badiola J, et al. Pulmonary but not subcutaneous delivery of BCG vaccine confers protection to tuberculosis-susceptible mice by an interleukin 17–dependent mechanism. J Infect Dis. (2016) 213:831–9. doi: 10.1093/infdis/jiv503, PMID: 26494773
125. Gopal R, Rangel-Moreno J, Slight S, Lin Y, Nawar HF, Junecko BAF, et al. Interleukin-17-dependent CXCL13 mediates mucosal vaccine–induced immunity against tuberculosis. Mucosal Immunol. (2013) 6:972–84. doi: 10.1038/mi.2012.135, PMID: 23299616
126. Gray J, Oehrle K, Worthen G, Alenghat T, Whitsett J, and Deshmukh H. Intestinal commensal bacteria mediate lung mucosal immunity and promote resistance of newborn mice to infection. Sci Transl Med. (2017) 9:eaaf9412. doi: 10.1126/scitranslmed.aaf9412, PMID: 28179507
127. Ardain A, Domingo-Gonzalez R, Das S, Kazer SW, Howard NC, Singh A, et al. Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis. Nature. (2019) 570:528–32. doi: 10.1038/s41586-019-1276-2, PMID: 31168092
128. Griffiths KL, Ahmed M, Das S, Gopal R, Horne W, Connell TD, et al. Targeting dendritic cells to accelerate T-cell activation overcomes a bottleneck in tuberculosis vaccine efficacy. Nat Commun. (2016) 7:13894. doi: 10.1038/ncomms13894, PMID: 28004802
129. Kaushal D and Mehra S. Didier P j., Lackner A a. The non-human primate model of tuberculosis. J Med Primatol. (2012) 41:191–201. doi: 10.1111/j.1600-0684.2012.00536.x, PMID: 22429048
130. Darrah PA, Zeppa JJ, Maiello P, Hackney JA, Wadsworth MH, Hughes TK, et al. Prevention of tuberculosis in macaques after intravenous BCG immunization. Nature. (2020) 577:95–102. doi: 10.1038/s41586-019-1817-8, PMID: 31894150
131. Irvine EB, O’Neil A, Darrah PA, Shin S, Choudhary A, Li W, et al. Robust IgM responses following intravenous vaccination with Bacille Calmette–Guérin associate with prevention of Mycobacterium tuberculosis infection in macaques. Nat Immunol. (2021) 22:1515–23. doi: 10.1038/s41590-021-01066-1, PMID: 34811542
132. Simonson AW, Zeppa JJ, Bucsan AN, Chao MC, Pokkali S, Hopkins F, et al. Intravenous BCG-mediated protection against tuberculosis requires CD4+ T cells and CD8α+ lymphocytes. J Exp Med. (2025) 222:e20241571. doi: 10.1084/jem.20241571, PMID: 39912921
133. Klein SL and Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. (2016) 16:626–38. doi: 10.1038/nri.2016.90, PMID: 27546235
134. Bini EI, Espinosa DM, Castillo BM, Payán JB, Colucci D, Cruz AF, et al. The influence of sex steroid hormones in the immunopathology of experimental pulmonary tuberculosis. PloS One. (2014) 9:e93831. doi: 10.1371/journal.pone.0093831, PMID: 24722144
135. Dibbern J, Eggers L, and Schneider BE. Sex differences in the C57BL/6 model of Mycobacterium tuberculosis infection. Sci Rep. (2017) 7, 10957. doi: 10.1038/s41598-017-11438-z, PMID: 28887521
136. Nieuwenhuizen NE, Zyla J, Zedler U, Bandermann S, Abu Abed U, Brinkmann V, et al. Weaker protection against tuberculosis in BCG-vaccinated male 129 S2 mice compared to females. Vaccine. (2021) 39:7253–64. doi: 10.1016/j.vaccine.2021.09.039, PMID: 34602301
137. Parvathy GH, Hertz D, Bhandiwad D, Eggers L, von Borstel L, Behrends J, et al. Sex differences in vaccine-induced immunity and protection against mycobacterium tuberculosis. The Journal of Infectious Diseases. (2025) 232(5):1187–1197. doi: 10.1093/infdis/jiaf277, PMID: 40569757
138. Tam A, Tanabe N, Churg A, Wright JL, Hogg JC, and Sin DD. Sex differences in lymphoid follicles in COPD airways. Respir Res. (2020) 21:46. doi: 10.1186/s12931-020-1311-8, PMID: 32033623
139. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. (2004) 350:2645–53. doi: 10.1056/NEJMoa032158, PMID: 15215480
140. Barnes PJ. Sex differences in chronic obstructive pulmonary disease mechanisms. Am J Respir Crit Care Med. (2016) 193:813–4. doi: 10.1164/rccm.201512-2379ED, PMID: 27082528
141. Dimitrijević M, Arsenović-Ranin N, Kosec D, Bufan B, Nacka-Aleksić M, Pilipović I, et al. Sex differences in Tfh cell help to B cells contribute to sexual dimorphism in severity of rat collagen-induced arthritis. Sci Rep. (2020) 10:1214. doi: 10.1038/s41598-020-58127-y, PMID: 31988383
142. Zychlinsky Scharff A, Rousseau M, Lacerda Mariano L, Canton T, Consiglio CR, Albert ML, et al. Sex differences in IL-17 contribute to chronicity in male versus female urinary tract infection. JCI Insight. (2019) 5:e122998. doi: 10.1172/jci.insight.122998, PMID: 31145099
143. Hoffmann J, Otte A, Thiele S, Lotter H, Shu Y, and Gabriel G. Sex differences in H7N9 influenza A virus pathogenesis. Vaccine. (2015) 33:6949–54. doi: 10.1016/j.vaccine.2015.08.044, PMID: 26319064
144. Kim SJ, Zou YR, Goldstein J, Reizis B, and Diamond B. Tolerogenic function of Blimp-1 in dendritic cells. J Exp Med. (2011) 208:2193–9. doi: 10.1084/jem.20110658, PMID: 21948081
145. Robinson DP, Lorenzo ME, Jian W, and Klein SL. Elevated 17β-estradiol protects females from influenza A virus pathogenesis by suppressing inflammatory responses. PloS Pathog. (2011) 7:e1002149. doi: 10.1371/journal.ppat.1002149, PMID: 21829352
146. Potluri T, Fink AL, Sylvia KE, Dhakal S, Vermillion MS, Vom Steeg L, et al. Age-associated changes in the impact of sex steroids on influenza vaccine responses in males and females. NPJ Vaccines. (2019) 4:29. doi: 10.1038/s41541-019-0124-6, PMID: 31312529
147. Foster AD, Haas M, Puliaeva I, Soloviova K, Puliaev R, and Via CS. Donor CD8 T cell activation is critical for greater renal disease severity in female chronic graft-vs.-host mice and is associated with increased splenic ICOS(hi) host CD4 T cells and IL-21 expression. Clin Immunol Orlando Fla. (2010) 136:61–73. doi: 10.1016/j.clim.2010.01.005, PMID: 20451460
148. Berghöfer B, Frommer T, Haley G, Fink L, Bein G, and Hackstein H. TLR7 ligands induce higher IFN-alpha production in females. J Immunol Baltim Md. (2006) 1950:177. doi: 10.4049/jimmunol.177.4.2088, PMID: 16887967
149. Meier A, Chang JJ, Chan ES, Pollard RB, Sidhu HK, Kulkarni S, et al. Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med. (2009) 15:955–9. doi: 10.1038/nm.2004, PMID: 19597505
150. Spiering AE and de Vries TJ. Why females do better: the X chromosomal TLR7 gene-dose effect in COVID-19. Front Immunol. (2021) 12:756262. doi: 10.3389/fimmu.2021.756262, PMID: 34858409
151. Hannah MF, Bajic VB, and Klein SL. Sex differences in the recognition of and innate antiviral responses to Seoul virus in Norway rats. Brain Behav Immun. (2008) 22:503–16. doi: 10.1016/j.bbi.2007.10.005, PMID: 18053684
152. Panchanathan R and Choubey D. Murine BAFF expression is up-regulated by estrogen and interferons: implications for sex bias in the development of autoimmunity. Mol Immunol. (2013) 53:15–23. doi: 10.1016/j.molimm.2012.06.013, PMID: 22784990
153. Abdullah M, Chai P-S, Chong M-Y, Tohit ERM, Ramasamy R, Pei CP, et al. Gender effect on in vitro lymphocyte subset levels of healthy individuals. Cell Immunol. (2012) 272:214–9. doi: 10.1016/j.cellimm.2011.10.009, PMID: 22078320
154. Dodd KC and Menon M. Sex bias in lymphocytes: Implications for autoimmune diseases. Front Immunol. (2022) 13:945762. doi: 10.3389/fimmu.2022.945762, PMID: 36505451
155. Dunn SE, Perry WA, and Klein SL. Mechanisms and consequences of sex differences in immune responses. Nat Rev Nephrol. (2024) 20:37–55. doi: 10.1038/s41581-023-00787-w, PMID: 37993681
156. Mayer-Barber KD, Andrade BB, Barber DL, Hieny S, Feng CG, Caspar P, et al. Innate and adaptive interferons suppress IL-1α and IL-1β production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection. Immunity. (2011) 35:1023–34. doi: 10.1016/j.immuni.2011.12.002, PMID: 22195750
157. Martinez AN, Mehra S, and Kaushal D. Role of interleukin 6 in innate immunity to Mycobacterium tuberculosis infection. J Infect Dis. (2013) 207:1253–61. doi: 10.1093/infdis/jit037, PMID: 23359591
158. Khader SA, Guglani L, Rangel-Moreno J, Gopal R, Junecko BAF, Fountain JJ, et al. IL-23 is required for long-term control of Mycobacterium tuberculosis and B cell follicle formation in the infected lung. J Immunol Baltim Md. (2011) 1950:187. doi: 10.4049/jimmunol.1101377, PMID: 22003199
159. Okamoto Yoshida Y, Umemura M, Yahagi A, O’Brien RL, Ikuta K, Kishihara K, et al. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J Immunol Baltim Md. (2010) 1950:184. doi: 10.4049/jimmunol.0903332, PMID: 20212094
160. Linge I, Dyatlov A, Kondratieva E, Avdienko V, Apt A, and Kondratieva T. B-lymphocytes forming follicle-like structures in the lung tissue of tuberculosis-infected mice: Dynamics, phenotypes and functional activity. Tuberculosis. (2017) 102:16–23. doi: 10.1016/j.tube.2016.11.005, PMID: 28061947
Keywords: antibodies, B cells, iBALT, sex differences, TLS, tuberculosis
Citation: Dutt TS, Krause R, Hertz D, Henao-Tamayo M, Leslie A and Schneider B (2026) B cells and iBALT in TB immunity & pathogenesis. Front. Immunol. 17:1743572. doi: 10.3389/fimmu.2026.1743572
Received: 10 November 2025; Accepted: 13 January 2026; Revised: 13 January 2026;
Published: 04 February 2026.
Edited by:
Sudhir Paul, University of Texas Health Science Center at Houston, United StatesReviewed by:
Bo Yan, Fudan University, ChinaIrina Linge, Central Tuberculosis Research Institute (RAMS), Russia
Copyright © 2026 Dutt, Krause, Hertz, Henao-Tamayo, Leslie and Schneider. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Alasdair Leslie, YWwubGVzbGllQGFocmkub3Jn; Marcela Henao-Tamayo, bWFyY2VsYS5oZW5hb190YW1heW9AY29sb3N0YXRlLmVkdQ==; Bianca Schneider, YnNjaG5laWRlckBmei1ib3JzdGVsLmRl
†These authors have contributed equally to this work and share first authorship
‡These authors have contributed equally to this work and share senior authorship